RADHA PHARMACEUTICALS INC

Radha Pharmaceuticals Inc. specializes in the manufacturing of sterile and oral solid-dose pharmaceutical preparations, with a demonstrated focus on generic drug products for federal healthcare and defense programs. The company’s core technical expertise lies in the formulation, production, and supply of FDA-regulated tablet dosage forms, including active pharmaceutical ingredients such as hydralazine HCl, fluconazole, fexofenadine, and clopidogrel bisulfate. Their operational capability includes end-to-end pharmaceutical manufacturing compliance with cGMP standards, quality control validation, and regulatory documentation for government procurement channels. A key differentiator is their consistent delivery of mission-critical medications under long-term, multi-option contracts, indicating robust supply chain reliability and regulatory adherence. The company maintains a strong relationship with the Department of Veterans Affairs, where it supplies essential therapeutics under cost-recovery and sales reporting frameworks, suggesting deep integration into VA’s pharmaceutical distribution and reimbursement systems. It also serves the Department of Defense and DLA Troop Support with on-demand pharmaceuticals for military medical readiness, often through competitive solicitations under SPE2D2 contract vehicles. These engagements reflect a proven ability to meet stringent military formulary requirements and just-in-time logistics demands. Radha Pharmaceuticals operates exclusively within NAICS 325412, Pharmaceutical Preparation Manufacturing, positioning itself as a niche supplier of generic solid oral dosage forms for government health programs. The company does not appear to engage in biologics, injectables, or novel drug delivery systems, instead focusing on high-volume, established therapeutics with well-documented regulatory pathways. As a 2L entity headquartered in Hauppauge, New York, Radha Pharmaceuticals functions as a mid-tier manufacturer without current federal certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is limited to its primary facility, and its market positioning is defined by reliability in fulfilling government pharmaceutical supply contracts rather than innovation or broad portfolio diversification.